Mercury Laboratories Ltd Share Price Today - Mercury Laboratories Ltd Stock Price Live NSE/BSE

Mercury Laboratories Ltd

NSE: BSE: 538964

₹780

(1.04%)

Fri, 13 Mar 2026, 01:59 pm

MTF 5xInvest in Mercury Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap926.4M

PE Ratio19.84

Dividend0.45

Health Technology

Pharmaceuticals: Major

24.5K

Mercury Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
93.60
Net Profit
3.14
P/B
1.83
Sector P/E
41.05
P/E
31.25
EV/EBITDA
12.55
Debt/Equity (Industry)
0.26
Interest Cover (Industry)
10.89
ROCE (Industry)
16.43
RONW (Industry)
14.36
ROE
6.01
ROCE
8.98
Debt/Equity
0.11
EPS (TTM)
41.22
Dividend Yield
0.45
Book Value
464.65
Interest Cover
9.47

Analysis

all

Pros

Dividends paid are thoroughly covered by earnings (13.5x coverage).
Mercury Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Mercury Laboratories is profitable, therefore cash runway is not a concern.
Mercury Laboratories is profitable, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (86.8%, greater than 20% of total debt).

Cons

Dividend payments have increased, but Mercury Laboratories only paid a dividend in the past 5 years.
Whilst dividend payments have been stable, Mercury Laboratories has been paying a dividend for less than 10 years.
Mercury Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Mercury Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	73.66	73.66	73.66	73.66	73.66
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	26.34	26.34	26.34	26.34	26.34
Government	0	0	0	0	0

Technical Analysis

RSI

49.91

MACD

-5.74

50 DMA

807.00

200 DMA

841.16

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	1056.70	945.40	887.20	834.10	775.90	722.80	611.50
Fibonacci	945.40	902.88	876.62	834.10	791.58	765.32	722.80
Camarilla	859.61	849.40	839.20	834.10	818.80	808.60	798.39

Pivots Level: Classic

+222.60

1056.70

+111.30

945.40

+53.10

887.20

834.10

Pivot Point

LTP: 800

-58.20

775.90

-111.30

722.80

-222.60

611.50

Moving Average

SMAEMA

Period

Value

10-EMA
792.90
20-EMA
797.76
30-EMA
801.44
50-EMA
808.99
100-EMA
823.18
200-EMA
840.79

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results
06 Jul 2025	dividend	Final Dividend - Rs. - 3.5	06 Aug 2025
14 May 2025	dividend	₹3.50 Dividend /Share	06 Aug 2025
14 May 2025	agm
24 Jul 2024	agm
28 May 2024	dividend	₹3.50 Dividend /Share	21 Sept 2024
05 May 2023	dividend	₹3.50 Dividend /Share	21 Sept 2023
05 May 2023	agm
26 May 2022	agm
26 May 2022	dividend	₹3.50 Dividend /Share	21 Sept 2022

Mercury Laboratories Ltd

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Divis Laboratories Ltd

Mercury Laboratories Ltd About

Mercury Laboratories is engaged into the manufacturing and export of wide range of Pharmaceutical items.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1982

Headquarters

CEO

SANJAY SHANTILAL PATEL

Employees

Contact

Website

http://www.mercurylabs.com

secretarial@mercurylabs.com, mllbrd@mercurylabs.co

Phone

91-22-66372841

Location

1st Floor 18 Shreeji Bhuwan 51, Princess Street Mangaladas Rd, Mumbai, Maharashtra, 400002

Year	History
1982	The Company was incorporated as Mercury Laboratories Pvt. Limited.
1992	The Company became a Public Ltd. company The company's name was changed to Mercury Laboratories Limited.
2015	Mercury Laboratories was listed in BSE.

Client Name	Order Side	QTY	Avg Price	Date
SHAH SHARAD KANAYALAL	Buy	8100	953.6	29 May 2023
KETAN BABULAL SHAH	Sell	9630	953.65	29 May 2023

Mercury Laboratories Ltd News

Mercury Labs Q3FY26 Net Profit Drops 16.4% to ₹99.75 Cr

Mercury Laboratories reported Q3FY26 net profit of ₹99.75 lakhs, down 16.4% YoY, despite revenue declining 6.2% to ₹1,835.03 lakhs. Nine-month performance showed strong recovery.

11 Feb 2026

co actions results

Mercury Laboratories Assigns Additional VP Role to Chief Operating Officer

Mercury Laboratories Limited has assigned an additional role of Vice President-Marketing Sales to Saurabh Mittal, who serves as Chief Operating Officer, effective November 17, 2025. The appointment involves a senior management personnel with over 15 years of corporate experience in marketing, business development, and system processes across established and start-up organizations.

17 Nov 2025

corporate governance

Mercury Laboratories Delays New Injectable Plant Commissioning by 13 Months to December 2026

Mercury Laboratories has deferred the commissioning of its new Small Volume Parenteral (SVPs) manufacturing plant by 13 months from the originally scheduled November 2025 to December 2026. The plant, located at Jarod with a capacity to manufacture 75 million units annually, involves an estimated cost of INR 30 crores. The delay is attributed to revisions in Schedule M guidelines by the Ministry of Health and Family Welfare, which mandated additional compliance and infrastructural requirements for pharmaceutical manufacturing facilities. The company states there is no material adverse impact on overall business operations due to the delay and is taking necessary steps to expedite project completion.

12 Nov 2025

stock

Mercury Laboratories Reports 69% Jump in Quarterly Net Profit to Rs 164.33 Lakhs

Mercury Laboratories Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The pharmaceutical company reported a net profit after tax of Rs 164.33 lakhs for the quarter, compared to Rs 96.76 lakhs in the previous quarter, representing a significant increase. Revenue from operations for the quarter stood at Rs 1,900.86 lakhs, up from Rs 1,813.54 lakhs in the previous quarter. For the half year period, net profit reached Rs 261.09 lakhs with revenue from operations at Rs 3,714.40 lakhs. The company's total comprehensive income for the quarter was Rs 164.00 lakhs. Basic earnings per share for the quarter was Rs 13.69 compared to Rs 8.06 in the previous quarter. The Board of Directors approved these results at their meeting held on November 11, 2025. The company operates in a single segment of pharmaceutical products and has paid-up equity share capital of Rs 120.00 lakhs with face value of Rs 10 per share.

12 Nov 2025

earnings

Mercury Laboratories Appoints Seema Salvi as Head of Injectable Production Department

Mercury Laboratories Limited appointed Ms. Seema Salvi as Head of the Injectable Production Department effective November 04, 2025. Salvi, aged 49, holds a Bachelor's degree in Pharmacy and brings over 26 years of experience in injection production. She was previously associated with Harson Laboratories India Pvt. Ltd. and Crescent Labs Pvt Ltd. The appointment is for full-time employment as part of the company's senior management personnel changes.

04 Nov 2025

corporate governance

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800